A
Alcista
Alcista · 25%EW
$75.40
Precio del escenario
$86.600
-1.472 (-1.70%)Al cierre
Loading chart…
- Máximo
- 88.400
- Apertura
- 88.210
- Precio medio ponderado por volumen
- 87.03
- Volumen
- 4.01M
- Capitalización
- 56.25B
- Mínimo
- 86.085
- Importe
- 348.77M
- EV/EBITDA, TTM
- 20.02
Edwards Lifesciences Corporation is a global structural heart company. The Company's work includes both surgical and transcatheter therapies. Its portfolio of repair and replacement technologies for aortic, mitral, tricuspid and pulmonic heart valves provides a set of treatment options to serve the diverse and complex patients in need. Its segment includes the United States, Europe, Japan, and the Rest of World. Its product categories include Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical. It provides transcatheter heart valve replacement technologies designed for the minimally invasive replacement of aortic heart valves. Its products include SAPIEN 3 Ultra RESILIA transcatheter heart valve, SAPIEN 3 Ultra transcatheter heart valve, SAPIEN 3 transcatheter heart valve and Alterra adaptive prestent. The TMTT category includes a PASCAL transcatheter repair system, EVOQUE tricuspid valve replacement system and others.
Análisis de IA of Edwards Lifesciences Corp (EW)
ComprarEdwards Lifesciences Corp is a good buy right now due to its current price of $86.6, which is well below the average analyst price target of $101.57, suggesting a potential upside of approximately 17.3%. Additionally, the forward P/E ratio is 25.641, indicating reasonable valuation compared to its growth prospects. The main risk is the recent decline in net income, which dropped to $241.9 million in Q2 2026 from $380.7 million in Q1 2026, reflecting a potential volatility in earnings.
Recomendaciones de analistas (21)
+11.45% de potencial alcista
Comprar
16 Comprar
4 Mantener
1 Vender
Actual: 86.60
Mínimo
84.00
Promedio
96.52
Máximo
105.00
Barclays
Sobreponderar
$110
2026-10-06
Barclays
2026-10-06
Precio objetivo
$110
Sobreponderar
Citi
Comprar
$110
2026-10-05
Citi
2026-10-05
Precio objetivo
$110
Comprar
UBS
Comprar
$110
2026-07-28
UBS
2026-07-28
Precio objetivo
$110
Comprar
Leerink
Superar al mercado
$101
2026-07-24
Leerink
2026-07-24
Precio objetivo
$101
Superar al mercado
JPMorgan
Sobreponderar
$105
2026-07-24
JPMorgan
2026-07-24
Precio objetivo
$105
Sobreponderar
Métricas de valoración
El PER previsto actual de Edwards Lifesciences Corp (EW) es 25.64, frente a su media de 5 años de 32.27.
Escenarios de precio de Alphio AI para EW
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con EW en cartera
Cronología de eventos
Noticias
9.510-07NewsfilterEdwards Lifesciences to Announce Q3 2026 Results
1.010-05NewsfilterEdwards Lifesciences Announces Investor Event at TCT Symposium
- 5.010-01Newsfilter
Edwards Receives FDA Approval for New Pediatric Heart Valve
- 8.509-10Newsfilter
Edwards Lifesciences Responds to TAVR Policy Update
7.009-07PRnewswireInvestigation into Edwards Lifesciences' Corporate Governance Breaches
Preguntas frecuentes sobre EW, respondidas por Alphio AI
Edwards Lifesciences Corporation is a global structural heart company. The Company's work includes both surgical and transcatheter therapies. Its portfolio of repair and replacement technologies for aortic, mitral, tricuspid and pulmonic heart valves provides a set of treatment options to serve the diverse and complex patients in need. Its segment includes the United States, Europe, Japan, and the Rest of World. Its product categories include Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical. It provides transcatheter heart valve replacement technologies designed for the minimally invasive replacement of aortic heart valves. Its products include SAPIEN 3 Ultra RESILIA transcatheter heart valve, SAPIEN 3 Ultra transcatheter heart valve, SAPIEN 3 transcatheter heart valve and Alterra adaptive prestent. The TMTT category includes a PASCAL transcatheter repair system, EVOQUE tricuspid valve replacement system and others. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).
Edwards Lifesciences Corp is a good buy right now due to its current price of $86.6, which is well below the average analyst price target of $101.57, suggesting a potential upside of approximately 17.3%. Additionally, the forward P/E ratio is 25.641, indicating reasonable valuation compared to its growth prospects. The main risk is the recent decline in net income, which dropped to $241.9 million in Q2 2026 from $380.7 million in Q1 2026, reflecting a potential volatility in earnings.
21 analysts cover EW: 16 rate it Buy, 4 Hold and 1 Sell. The average price target is 96.52.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.